NEUROPATHIC PAIN SECTION Original Research Article Early Pain Reduction Can Predict Treatment Response: Results of Integrated Efficacy Analyses of a Once-Daily Gastroretentive Formulation of Gabapentin in Patients with Postherpetic Neuralgia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?

  2012cited by this paper
• Effect of study country on efficacy and adverse event profile of once-daily gabapentin extended-release (G-ER) for the treatment of postherpetic neuralgia (PHN)

  2011cited by this paper
• Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

  2010cited by this paper
• Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia

  2010cited by this paper
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

  2010cited by this paper
• Treatment of neuropathic pain: an overview of recent guidelines.

  2009cited by this paper
• The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?

  2009cited by this paper
• Efficacy and Tolerability of Gastric-retentive Gabapentin for the Treatment of Postherpetic Neuralgia: Results of a Double-blind, Randomized, Placebo-controlled Clinical Trial

  2009cited by this paper
• Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.

  2008cited by this paper
• Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.

  2006cited by this paper
• Neuropathic pain: a practical guide for the clinician

  2006cited by this paper
• Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

  2006cited by this paper
• Early response and 8‐week treatment outcome in GAD

  2006cited by this paper
• Efficacy and Safety of a Novel Once-Daily Extended-Release Ciprofloxacin Tablet Formulation for Treatment of Uncomplicated Urinary Tract Infection in Women

  2005cited by this paper
• Practice Parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology*

  2004cited by this paper
• Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder.

  2002cited by this paper
• Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale

  2001cited by this paper
• Fluoxetine Versus Moclobemide: Cross-Comparison Between the Time Courses of Improvement

  1999cited by this paper
• Towards a mechanism-based classification of pain?

  1998cited by this paper
• Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.

  1995cited by this paper
• A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin Is the Underlying Cause of the Lack of Proportionality Between Increasing Dose and Drug Levels in Plasma

  1993cited by this paper
• Early treatment response in anxious outpatients treated with diazepam

  1985cited by this paper

• Transcranial direct current stimulation for provoked vestibulodynia: What roles do psychosexual factors play in treatment response?

  2021cites this paper
• Pregabalin for neuropathic pain in adults.

  2019cites this paper
• Gabapentin for chronic neuropathic pain in adults.

  2017cites this paper
• Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.

  2015cites this paper
• Gabapentin for chronic neuropathic pain and fibromyalgia in adults.

  2014cites this paper